Companies › Alfasigma
1 active drug program in 7 registered trials: 4 Phase 3, 2 Phase 4, 1 Phase 2; Immunology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Filgotinib Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase TYK2 inhibitor | JAK1, JAK2, TYK2, JAK3 | Phase 3 | Polyarticular Course Juvenile Idiopathic Arthritis; Juvenile Idiopathic Arthritis (JIA); Ulcerative Colitis; Axial Spondyloarthritis … | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04985435 | Filgotinib | Phase 4 | Rheumatoid Arthritis | Immunology | Sep 2025 |
| NCT06285539 | Filgotinib | Phase 2 | Behcet's Disease | Immunology | Dec 2026 |
| NCT07554495 | Filgotinib | Phase 3 | Polyarticular Course Juvenile Idiopathic Arthritis | Immunology | Jun 2027 |
| NCT07553182 | Filgotinib | Phase 3 | Juvenile Idiopathic Arthritis (JIA) | Immunology | Dec 2027 |
| NCT06865417 | Filgotinib | Phase 3 | Ulcerative Colitis | Immunology | Jun 2028 |
| NCT05785611 | Filgotinib | Phase 3 | Axial Spondyloarthritis | Immunology | Dec 2028 |
| NCT06687551 | Filgotinib | Phase 4 | Rheumatoid Arthritis (RA | Immunology | Apr 2029 |
Sun Pharma Japan Alumis Pharvaris Netherlands AUG Therapeutics Lynk Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.